ArriVent BioPharma Stock Forecast

Stock Price Forecast

The 6 analysts with 12-month price forecasts for ArriVent BioPharma stock have an average target of 39, with a low estimate of 36 and a high estimate of 45. The average target predicts an increase of 105.80% from the current stock price of 18.95.

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$36	$39	$39	$45
Change	+89.97%	+105.80%	+105.80%	+137.47%

Analyst Ratings

The average analyst rating for ArriVent BioPharma stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Oct '24	Nov '24	Dec '24	Jan '25	Feb '25	Mar '25
Strong Buy	4	4	4	4	4	5
Buy	1	1	1	1	1	1
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	5	5	5	5	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Kalpit Patel B. Riley Securities	B. Riley Securities	Strong Buy Initiates $37	Strong Buy	Initiates	$37	+95.25%	Mar 20, 2025
Michael Schmidt Guggenheim	Guggenheim	Strong Buy Initiates $45	Strong Buy	Initiates	$45	+137.47%	Mar 10, 2025
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $39	Strong Buy	Reiterates	$39	+105.80%	Mar 7, 2025
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $36 → $39	Strong Buy	Maintains	$36 → $39	+105.80%	Jan 22, 2025
Robert Burns HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $36	Strong Buy	Reiterates	$36	+89.97%	Nov 15, 2024

More Analyst Ratings

Financial Forecast

Revenue This Year

291.93M

from 178.96M

63.13%

from 178.96M

Revenue Next Year

n/a

from 291.93M

EPS This Year

-2.98

from -2.56

EPS Next Year

-3.59

from -2.98

Fiscal Year	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026	FY 2027	FY 2028	FY 2029
Period Ending	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026	Dec 31, 2027	Dec 31, 2028	Dec 31, 2029
Revenue	-	4.95M	73.56M	178.96M	291.93M
Revenue Growth	-	-	1,386.92%	143.29%	63.13%	-	-	-
EPS	-96.75	-28.90	-32.38	-2.56	-2.98	-3.59	-2.07	0.48
EPS Growth	-	-	-	-	-	-	-	-
Forward PE	-	-	-	-	-	-	-	39.53
No. Analysts	-	-	-	-	9	8	7	4

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027
High	n/a	10.2M	80.5M
Avg	n/a	4.9M	73.6M
Low	n/a	n/a	66.2M

Revenue Growth

Revenue Growth	2025	2026	2027
High	-	-	1,526.5%
Avg	-	-	1,386.9%
Low	-	-	1,239.2%

EPS Forecast

EPS	2025	2026	2027
High	-1.83	-1.78	-0.42
Avg	-2.98	-3.59	-2.07
Low	-3.89	-4.55	-3.45

EPS Growth

EPS Growth	2025	2026	2027
High	-	-	-
Avg	-	-	-
Low	-	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.